达格列净对血糖控制不佳的2型糖尿病伴肥胖患者胰岛功能的影响

doi:10.20047/j.issn1673-7210.2022.33.16

摘要
图/表
参考文献(28)
相关文章 (15)

全文: PDF (542 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探究达格列净对血糖控制不佳的2型糖尿病（T2DM）伴肥胖患者胰岛功能的影响。方法选取江苏省淮安市肿瘤医院2019年6月至2021年3月收治的73例T2DM伴肥胖患者作为研究对象。按照随机数字表法将其分为试验组（37例）、对照组（36例）。对照组予以利司那肽治疗，试验组予以达格列净联合利司那肽治疗。比较两组治疗前及治疗6个月后胰岛素抵抗指数（HOMA-IR）、胰岛β细胞功能指数（HOMA-β）、空腹血糖、餐后2 h血糖、糖化血红蛋白（HbA1c）、体重指数（BMI）、体脂率；比较两组血糖达标时间；记录患者用药期间的不良反应。结果治疗后，两组HOMA-IR、空腹血糖、餐后2 h血糖、HbA1c、BMI及体脂率低于治疗前，且试验组低于对照组（P ＜ 0.05）；两组HOMA-β高于治疗前，且试验组高于对照组（P ＜ 0.05）；试验组血糖达标时间短于对照组（P ＜ 0.05）。两组总不良反应发生率比较，差异无统计学意义（P ＞ 0.05）。结论达格列净治疗血糖控制不佳的T2DM伴肥胖患者，可有效改善患者胰岛功能，调节血糖水平，改善肥胖程度且安全性良好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周洁吴新华严妍时雯朱平▲

关键词 ： 2型糖尿病, 达格列净, 利司那肽, 血糖控制不佳, 肥胖

Abstract：Objective To explore the effect of Dapagliflozin on islet function in type 2 diabetic mellitus (T2DM) patients with obesity and poor glucose control. Methods A total of 73 T2DM patients with obesity and poor glucose control treated in Huai’an Cancer Hospital of Jiangsu Province from June 2019 to March 2021 were selected as the research objects. According to the random number table method, they were divided into experimental group (37 cases) and control group (36 cases). The control group was treated with Risenatide, experimental group was treated with Dapagliflozin combined with Risenatide. The insulin resistance index (HOMA-IR), islet β-cell function index (HOMA-β), fasting blood glucose and 2-h postprandial blood glucose, glycosylated hemoglobin (HbA1c), body mass index (BMI), and body fat rate were compared between two groups before treatment and six months after treatment; the time to blood glucose target between two groups were compared; the adverse reactions during treatment were recorded. Results After treatment, HOMA-IR, fasting blood glucose, 2-h postprandial blood glucose, HbA1c, BMI, and body fat rate in two groups were lower than those before treatment, and those in the experimental group were lower than those in control group (P ＜ 0.05). HOMA-β in two groups was higher than that before treatment, and that in experimental group was higher than that in control group (P ＜ 0.05). There was no significant difference in the incidence of total adverse reactions between two groups (P ＞ 0.05). Conclusion Dapagliflozin in the treatment of T2DM patients with obesity and poor glucose control can effectively improve the islet function, regulate the blood glucose level, improve the degree of obesity and have good safety.

Key words： Type 2 diabetes mellitus Dapagliflozin Risenatide Poor blood sugar control Obesity

基金资助:江苏省淮安市卫生健康科研项目（HAWJ201927）；
江苏省淮安市自然科学研究计划（指导性）项目（ HABZ201 910）。

通讯作者: ▲通讯作者

作者简介: 周洁（1989.3-），女，硕士；研究方向：内分泌。

引用本文:

周洁吴新华严妍时雯朱平▲. 达格列净对血糖控制不佳的2型糖尿病伴肥胖患者胰岛功能的影响[J]. 中国医药导报, 2022, 19(33): 75-78.
ZHOU Jie WU Xinhua YAN Yan SHI Wen ZHU Ping▲. Effect of Dapagliflozin on islet function in type 2 diabetes mellitus with obesity and poor glucose control. 中国医药导报, 2022, 19(33): 75-78.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2022.33.16 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I33/75